Fatostatin A is a novel, potent and cell permeable inhibitor of SREBP (Sterol regulatory element-binding protein) activation with anticancer activity.

TVB-3664 (TVB3664 ) is a novel and potent fatty acid synthase (FASN) inhibitor that is orally bioavailable, reversible, and selective.

Fatostatin HBr, the hydrobromide salt of fatostatin A, is a novel, potent and cell permeable inhibitor of SREBP (Sterol regulatory element-binding protein) activation by directly binding SCAP and blocking its ER-to-Golgi transport with IC50 of 2.5 and 10 μM in mammalian cells.

TVB-3166 is a novel, potent, orally bioavailable, reversible and selective inhibitor of fatty acid synthase (FASN) inhibitor (IC50s of 42 nM and 81 nM in biochemical and cellular assay, respectively. ), it acts by inducing apoptosis, inhibiting anchorage-independent cell growth under lipid-rich conditions, and inhibiting in-vivo xenograft tumor growth.

Orlistat (also known as tetrahydrolipstatin, or Ro 18-0647, Lipase Inhibitor, THL ) is a potent and general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice.

Denifanstat (TVB-2640; FASN-IN-2; ASC-40; TVB2640) is a novel, potent and orally bioactive fatty acid synthase (FASN) inhibitor with potential anticancer activity and may also be used for the Treatment of Nonalcoholic Steatohepatitis.